Filter

Refine by collections

  • 100 years of Insulin and Glucagon (5)

Refine by date

—

Refine by access

  • Print
  • Save

Search Results

You are looking at 1 - 5 of 5 items for :

  • molecular markers x
  • 100 years of Insulin and Glucagon x
  • Refine by access: All content x
Clear All
Wenzel M Hackeng Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Wenzel M Hackeng in
Google Scholar
PubMed Close
,
Lodewijk A A Brosens Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands

Search for other papers by Lodewijk A A Brosens in
Google Scholar
PubMed Close
, and
Koen M A Dreijerink Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
Department of Endocrinology, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, The Netherlands

Search for other papers by Koen M A Dreijerink in
Google Scholar
PubMed Close

, have not been studied for insulinoma. Several immunohistochemical markers may be of use in separating indolent from aggressive insulinomas. Diffuse cytoplasmic insulin expression is seen in 90–100% of indolent insulinomas ( Roth et al. 1992

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-22-0321
Volume/Issue:
Volume 30: Issue 5
Free access
Bence Sipos Department of Medical Oncology and Pneumology (Internal Medicine VIII), University Hospital Tubingen, Tübingen, Germany
ENETS Center of Excellence, University Hospital Tübingen, Tübingen, Germany

Search for other papers by Bence Sipos in
Google Scholar
PubMed Close
and
Günter Klöppel Department of Pathology, Technical University Munich, Munich, Germany

Search for other papers by Günter Klöppel in
Google Scholar
PubMed Close

potential. Glucagon serum level may serve as tumor marker for monitoring patients during surveillance. Some anecdotal GCHN cases with liver metastasis are known in the scientific community, but none of these cases has been published so far ( Yu 2018

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0032
Volume/Issue:
Volume 30: Issue 8
Free access
Francesca Marini Fondazione FIRMO Onlus, Italian Foundation for the Research on Bone Diseases, Florence, Italy

Search for other papers by Francesca Marini in
Google Scholar
PubMed Close
,
Francesca Giusti Donatello Bone Clinic, Villa Donatello Hospital, Sesto Fiorentino, Italy

Search for other papers by Francesca Giusti in
Google Scholar
PubMed Close
, and
Maria Luisa Brandi Fondazione FIRMO Onlus, Italian Foundation for the Research on Bone Diseases, Florence, Italy
Donatello Bone Clinic, Villa Donatello Hospital, Sesto Fiorentino, Italy

Search for other papers by Maria Luisa Brandi in
Google Scholar
PubMed Close

-fold higher than wild-type littermates, expressing embryonic markers ( Vuguin & Charron 2011 ). The presence of pancreatic tumors in GCHN is usually associated with abdominal pain and discomfort but not with the glucagonoma syndrome, since glucagon

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0245
Volume/Issue:
Volume 31: Issue 5
Restricted access
Christine Sempoux Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Search for other papers by Christine Sempoux in
Google Scholar
PubMed Close
and
Günter Klöppel Department of Pathology, Technical University Munich, Munich, Germany

Search for other papers by Günter Klöppel in
Google Scholar
PubMed Close

the ducts. These nesidioblastotic features can be seen in the adult pancreas and are even more pronounced in the neonate pancreas. They usually need immunostaining for pancreatic hormones or neuroendocrine markers to be clearly identified ( Fig. 1F

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0034
Volume/Issue:
Volume 30: Issue 9
Free access
Krystallenia I Alexandraki Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed Close
,
Gregory A Kaltsas Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed Close
, and
Simona Grozinsky-Glasberg Department of Endocrinology and Metabolism, Neuroendocrine Tumor Unit, ENETS Center of Excellence, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed Close

), second-generation SSAs (pasireotide), molecular-targeted therapies (MTT) (mTOR inhibitors (mTORi; everolimus)), or tyrosine kinase inhibitors (TKI; sunitinib) have been used. A further systemic targeted therapy is peptide receptor radionuclide therapy

Article Type:
Review Article
Collections:
100 years of Insulin and Glucagon
DOI:
https://doi.org/10.1530/ERC-23-0020
Volume/Issue:
Volume 30: Issue 9
Free access